Pharmacogenetics-based therapeutic recommendations -: ready for clinical practice?

被引:107
作者
Kirchheiner, J
Fuhr, U
Brockmöller, J
机构
[1] Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany
[2] Univ Gottingen, Dept Clin Pharmacol, D-37075 Gottingen, Germany
关键词
D O I
10.1038/nrd1801
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Although considerable progress has been made in basic pharmacogenetic research, less has been demonstrated in the application of pharmacogenetics (PGx)based diagnostics to drug development and in clinical practice. There are drugs that are currently used in the clinic for which individualized therapy could be beneficial based on PGx data. However, specific, actionable recommendations on how to implement individualized therapy - particularly with respect to dosage - still have to be developed. Moreover, to apply PGx efficiently in clinical drug development, and later in drug therapy, study designs and the generation and handling of PGx data need to become more standardized. Here, we argue for the development of concise guidelines for implementation of PGx analyses in drug development and therapy.
引用
收藏
页码:639 / 647
页数:9
相关论文
共 33 条
[1]  
Brockmoller J, 2000, Pharmacogenomics, V1, P125, DOI 10.1517/14622416.1.2.125
[2]   Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology [J].
De Laurentiis, M. ;
Cancello, G. ;
Zinno, L. ;
Montagna, E. ;
Malorni, L. ;
Esposito, A. ;
Pennacchio, R. ;
Silvestro, L. ;
Giuliano, M. ;
Giordano, A. ;
Caputo, F. ;
Accurso, A. ;
De Placido, Sabino .
ANNALS OF ONCOLOGY, 2005, 16 :7-13
[3]   Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6 [J].
Dilger, K ;
Greiner, B ;
Fromm, MF ;
Hofmann, U ;
Kroemer, HK ;
Eichelbaum, M .
PHARMACOGENETICS, 1999, 9 (05) :551-559
[4]   Moving towards individualized medicine with pharmacogenomics [J].
Evans, WE ;
Relling, MV .
NATURE, 2004, 429 (6990) :464-468
[5]   The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population [J].
Fukuda, T ;
Nishida, Y ;
Zhou, Q ;
Yamamoto, I ;
Kondo, S ;
Azuma, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (02) :175-180
[6]   Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? [J].
Gardiner, SJ ;
Begg, EJ .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (05) :365-369
[7]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[8]   A new system for grading recommendations in evidence based guidelines [J].
Harbour, R ;
Miller, J .
BRITISH MEDICAL JOURNAL, 2001, 323 (7308) :334-336
[9]   Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity [J].
Hughes, DA ;
Vilar, FJ ;
Ward, CC ;
Alfirevic, A ;
Park, BK ;
Pirmohamed, M .
PHARMACOGENETICS, 2004, 14 (06) :335-342
[10]   Whole-genome scan, in a complex disease, using 11,245 single-nucleotide polymorphisms: Comparison with microsatellites [J].
John, S ;
Shephard, N ;
Liu, GY ;
Zeggini, E ;
Cao, MQ ;
Chen, WW ;
Vasavda, N ;
Mills, T ;
Barton, A ;
Hinks, A ;
Eyre, S ;
Jones, KW ;
Ollier, W ;
Silman, A ;
Gibson, N ;
Worthington, J ;
Kennedy, GC .
AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (01) :54-64